Advertisement

Psychopharmacology

, Volume 196, Issue 3, pp 417–429 | Cite as

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia

  • Olivia Frånberg
  • Charlotte Wiker
  • Monica M. Marcus
  • Åsa Konradsson
  • Kent Jardemark
  • Björn Schilström
  • Mohammed Shahid
  • Erik H. F. Wong
  • Torgny H. Svensson
Original Investigation

Abstract

Rationale

Asenapine is a novel psychopharmacologic agent being developed for the treatment of schizophrenia and bipolar disorder.

Materials and methods

The present study was undertaken to investigate the effects of asenapine using animal models predictive of antipsychotic efficacy (conditioned avoidance response [CAR]) and extrapyramidal side effects (EPS; catalepsy). In parallel, the effects of asenapine on regional dopamine output using in vivo microdialysis in freely moving rats, dopamine output in the core and shell subregions of nucleus accumbens (NAc) using in vivo voltammetry in anesthetized rats, and N-methyl-d-aspartate (NMDA)-induced currents in pyramidal neurons of the medial prefrontal cortex (mPFC) using the electrophysiological technique intracellular recording in vitro were assessed.

Results

Asenapine (0.05–0.2 mg/kg, subcutaneous [s.c.]) induced a dose-dependent suppression of CAR (no escape failures recorded) and did not induce catalepsy. Asenapine (0.05–0.2 mg/kg, s.c.) increased dopamine efflux in both the mPFC and the NAc. Low-dose asenapine (0.01 mg/kg, intravenous [i.v.]) increased dopamine efflux preferentially in the shell compared to the core of NAc, whereas at a higher dose (0.05 mg/kg, i.v.), the difference disappeared. Finally, like clozapine (100 nM), but at a considerably lower concentration (5 nM), asenapine significantly potentiated the NMDA-induced responses in pyramidal cells of the mPFC.

Conclusions

These preclinical data suggest that asenapine may exhibit highly potent antipsychotic activity with very low EPS liability. Its ability to increase both dopaminergic and glutamatergic activity in rat mPFC suggests that asenapine may possess an advantageous effect not only on positive symptoms in patients with schizophrenia, but also on negative and cognitive symptoms.

Keywords

Asenapine Schizophrenia Rat Microdialysis CAR Catalepsy Voltammetry Electrophysiology Dopamine Glutamate 

Notes

Acknowledgements

This research was supported by the Swedish Research Council (grant no. 4747), the Karolinska Institutet, Organon Laboratories and Pfizer. Drs. Kent Jardemark and Björn Schilström were supported by grants from the Scandinavian College of Neuro-Psychopharmacology and the Lundbeck Foundation. We thank Dr. Marie-Louise Wadenberg for valuable discussions and Mrs. Anna Malmerfelt and Mrs. Ann-Chatrine Samuelsson for skillful technical assistance.

All experiments were approved by, and conducted in accordance with, the local Animal Ethics Committee, Stockholm North, and the Karolinska Institutet, Sweden.

References

  1. Ahlenius S, Hillegaart V (1986) Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 24:1409–1415PubMedCrossRefGoogle Scholar
  2. Arvanov VL, Wang RY (1998) M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-d-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197–209PubMedCrossRefGoogle Scholar
  3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997) Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226–234PubMedGoogle Scholar
  4. Broekkamp CL, De Graaf JS, van Delft AM (1990) Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 40(5):544–549PubMedGoogle Scholar
  5. Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:165–173PubMedGoogle Scholar
  6. Castner SA, Williams GV, Goldman-Rakic PS (2000) Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287:2020–2022PubMedCrossRefGoogle Scholar
  7. Chen L, Yang CR (2002) Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324–2336PubMedGoogle Scholar
  8. Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM (1990) Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 35(3):607–615PubMedCrossRefGoogle Scholar
  9. Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564PubMedCrossRefGoogle Scholar
  10. Deutch AY (1993) Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson’s disease. J Neural Transm Gen Sect 91:197–221PubMedCrossRefGoogle Scholar
  11. Deutch AY, Cameron DS (1992) Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46:49–56PubMedCrossRefGoogle Scholar
  12. Deutch AY, Lee MC, Iadarola MJ (1992) Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 46:49–56Google Scholar
  13. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917–6922PubMedCrossRefGoogle Scholar
  14. Eltayb A, Wadenberg ML, Svensson TH (2005) Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose l-dopa. Biol Psychiatry 58:337–343PubMedCrossRefGoogle Scholar
  15. Emamian ES, Karayiorgou M, Gogos JA (2004) Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J Neurosci 24:1561–1564PubMedCrossRefGoogle Scholar
  16. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76PubMedGoogle Scholar
  17. Gessa GL, Canu A, Del Zompo M, Burrai C, Serra G (1991) Lack of acute antipsychotic effect of Sch 23390, a selective dopamine D1 receptor antagonist. Lancet 6;337(8745):854–855Google Scholar
  18. Goldman-Rakic PS, Muly EC, Williams GV (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31:295–301PubMedCrossRefGoogle Scholar
  19. Gonon FG (1988) Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24:19–28PubMedCrossRefGoogle Scholar
  20. Gonon F, Buda M, Pujol JF (1984) Treated carbon fibre electrodes for measuring catechols and ascorbic acid. In: Marsden CA (ed) Measurement of neurotransmittor release in vivo. Wiley, Chichester, UK, pp 153–171Google Scholar
  21. Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) 124:74–86CrossRefGoogle Scholar
  22. Hertel P, Fagerquist MV, Svensson TH (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286:105–107PubMedCrossRefGoogle Scholar
  23. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120(2):128–133PubMedCrossRefGoogle Scholar
  24. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225PubMedCrossRefGoogle Scholar
  25. Joyce JN, Millan MJ (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917–925PubMedCrossRefGoogle Scholar
  26. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796PubMedGoogle Scholar
  27. Karlsson P, Smith L, Farde L, Härnryd C, Sedvall G, Wiesel F-A (1995) Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121:309–316PubMedCrossRefGoogle Scholar
  28. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE (2006) Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60:102–108PubMedCrossRefGoogle Scholar
  29. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774–781PubMedGoogle Scholar
  30. Li C (1964) Introduction to experimental statistics. McGraw-Hill, New York, USA, pp 207–226Google Scholar
  31. Liégeois JF, Ichikawa J, Meltzer HY (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157–165PubMedCrossRefGoogle Scholar
  32. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168:571–579PubMedCrossRefGoogle Scholar
  33. Marcus MM, Nomikos GG, Svensson TH (1996) Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol 6:29–38PubMedCrossRefGoogle Scholar
  34. Marcus MM, Nomikos GG, Svensson TH (2000) Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur Neuropsychopharmacol 10:245–253PubMedCrossRefGoogle Scholar
  35. Marcus MM, Malmerfelt A, Nyberg S, Svensson TH (2002) Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. Eur Neuropsychopharmacol 12:379–386PubMedCrossRefGoogle Scholar
  36. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH (2005) Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315–327PubMedCrossRefGoogle Scholar
  37. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255PubMedGoogle Scholar
  38. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755–1760PubMedCrossRefGoogle Scholar
  39. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427–436PubMedCrossRefGoogle Scholar
  40. Ninan I, Wang RY (2003) Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. Eur J Neurosci 17:1306–1312PubMedCrossRefGoogle Scholar
  41. Ninan I, Jardemark KE, Wang RY (2003) Differential effects of atypical and typical antipsychotic drugs on N-methyl-d-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48:66–79PubMedCrossRefGoogle Scholar
  42. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 115:147–156CrossRefGoogle Scholar
  43. Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444–1449PubMedGoogle Scholar
  44. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, New York, USAGoogle Scholar
  45. Potkin SG, Fleming K, Binneman B, Keller DS, Alphs L, Panagides J (2006) Asenapine effects on cognitive function during acute episodes of schizophrenia: a randomized placebo- and risperidone-controlled trial. Neuropsychopharmacology 31:251Google Scholar
  46. Potkin SG, Cohen M, Panagides J (2007) Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry (in press)Google Scholar
  47. Robertson GS, Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46(2):315–328PubMedCrossRefGoogle Scholar
  48. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403–1410PubMedGoogle Scholar
  49. Salmi P, Samuelsson J, Ahlenius S (1994) A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. J Pharmacol Toxicol Methods 32:155–159PubMedCrossRefGoogle Scholar
  50. Schilström B, Nomikos GG, Nisell M, Hertel P, Svensson TH (1998) N-methyl-d-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82:781–789PubMedCrossRefGoogle Scholar
  51. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57–73CrossRefGoogle Scholar
  52. Sedvall G, Farde L (1995) Chemical brain anatomy in schizophrenia. Lancet 346:743–749PubMedCrossRefGoogle Scholar
  53. Shahid M, Summer BEH, Wong EHF, Henry B (2007a) Asenapine displays distinctive induction patterns of c-fos mRNA expression in rat forebrain regions. Biol Psychiatry 61(8):256S–256S 826 Suppl. 2Google Scholar
  54. Shahid M, Walker GB, Zorn SH, Wong EHF (2007b) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol (in press)Google Scholar
  55. Siegel S, Castellan JNJ (1988) Nonparametric statistics for the behavioral sciences. McGraw-Hill, New York, USAGoogle Scholar
  56. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25–43PubMedGoogle Scholar
  57. Svensson TH (2003a) Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. Clinical Neuroscience Research 3:34–36CrossRefGoogle Scholar
  58. Svensson TH (2003b) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145–1158PubMedCrossRefGoogle Scholar
  59. Tandon R (2002) Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr Q 73:297–311PubMedCrossRefGoogle Scholar
  60. Thomas DR and Hagan JJ (2004) 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3(1):81–90PubMedCrossRefGoogle Scholar
  61. Wadenberg ML, Ahlenius S, Svensson TH (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacology (Berl) 110:273–279CrossRefGoogle Scholar
  62. Wadenberg ML, Hicks PB (1999) The conditioned avoidance response test re evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851–862PubMedCrossRefGoogle Scholar
  63. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422–429CrossRefGoogle Scholar
  64. Wadenberg MG, Browning JL, Young KA, Hicks PB (2001a) Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 68:363–370PubMedCrossRefGoogle Scholar
  65. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001b) Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633–641PubMedCrossRefGoogle Scholar
  66. Wadenberg ML, Wiker C, Svensson TH (2007) Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha 2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10(2):191–202PubMedCrossRefGoogle Scholar
  67. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE (2001) Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50:825–844PubMedCrossRefGoogle Scholar
  68. Woolley ML, Marsden CA, Fone KC (2004) 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord 3(1):59–79PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Olivia Frånberg
    • 1
  • Charlotte Wiker
    • 1
  • Monica M. Marcus
    • 1
  • Åsa Konradsson
    • 1
  • Kent Jardemark
    • 1
  • Björn Schilström
    • 1
  • Mohammed Shahid
    • 2
  • Erik H. F. Wong
    • 3
  • Torgny H. Svensson
    • 1
  1. 1.Department of Physiology and Pharmacology, Section of NeuropsychopharmacologyKarolinska InstitutetStockholmSweden
  2. 2.Organon Laboratories LtdLanarkshireUK
  3. 3.Pfizer Global R&DAnn ArborUSA

Personalised recommendations